12/1
08:35 am
prta
Prothena (NASDAQ:PRTA) had its price target raised by analysts at Citizens Jmp from $11.00 to $19.00. They now have a "market outperform" rating on the stock.
Low
Report
Prothena (NASDAQ:PRTA) had its price target raised by analysts at Citizens Jmp from $11.00 to $19.00. They now have a "market outperform" rating on the stock.
12/1
07:19 am
prta
Prothena (NASDAQ:PRTA) was given a new $19.00 price target on by analysts at Deutsche Bank Aktiengesellschaft.
Medium
Report
Prothena (NASDAQ:PRTA) was given a new $19.00 price target on by analysts at Deutsche Bank Aktiengesellschaft.
12/1
07:19 am
prta
Prothena (NASDAQ:PRTA) was given a new $19.00 price target on by analysts at JMP Securities.
Medium
Report
Prothena (NASDAQ:PRTA) was given a new $19.00 price target on by analysts at JMP Securities.
12/1
06:04 am
prta
Prothena (NASDAQ:PRTA) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
Medium
Report
Prothena (NASDAQ:PRTA) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
11/22
05:37 am
prta
Why The Narrative Around Prothena Is Shifting After Analysts Raise Targets and Clinical Updates [Yahoo! Finance]
Low
Report
Why The Narrative Around Prothena Is Shifting After Analysts Raise Targets and Clinical Updates [Yahoo! Finance]
11/21
05:31 am
prta
Prothena (NASDAQ:PRTA) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.
Medium
Report
Prothena (NASDAQ:PRTA) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.
11/19
04:34 pm
prta
Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025 [Yahoo! Finance]
Low
Report
Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025 [Yahoo! Finance]
11/19
04:05 pm
prta
Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025
Low
Report
Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025
11/18
01:19 pm
prta
Prothena (NASDAQ:PRTA) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Prothena (NASDAQ:PRTA) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
11/11
09:00 am
prta
Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA
Low
Report
Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA
11/8
01:17 pm
prta
Low
Report
11/7
07:07 pm
prta
Prothena Q3 Earnings Miss Estimates, Pipeline Progress in Focus [Yahoo! Finance]
Low
Report
Prothena Q3 Earnings Miss Estimates, Pipeline Progress in Focus [Yahoo! Finance]
11/7
03:01 pm
prta
Prothena (NASDAQ:PRTA) had its price target raised by analysts at HC Wainwright from $20.00 to $30.00. They now have a "buy" rating on the stock.
Medium
Report
Prothena (NASDAQ:PRTA) had its price target raised by analysts at HC Wainwright from $20.00 to $30.00. They now have a "buy" rating on the stock.
11/7
02:22 pm
prta
Prothena (NASDAQ:PRTA) had its price target raised by analysts at Royal Bank Of Canada from $10.00 to $11.00. They now have a "sector perform" rating on the stock.
Medium
Report
Prothena (NASDAQ:PRTA) had its price target raised by analysts at Royal Bank Of Canada from $10.00 to $11.00. They now have a "sector perform" rating on the stock.
11/7
01:15 am
prta
Prothena (NASDAQ:PRTA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Prothena (NASDAQ:PRTA) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/6
04:05 pm
prta
Prothena Reports Third Quarter 2025 Financial Results and Business Highlights
Medium
Report
Prothena Reports Third Quarter 2025 Financial Results and Business Highlights
10/30
04:05 pm
prta
Prothena to Report Third Quarter 2025 Financial Results on November 6
Low
Report
Prothena to Report Third Quarter 2025 Financial Results on November 6
10/28
10:58 am
prta
Prothena (NASDAQ:PRTA) was given a new $36.00 price target on by analysts at UBS Group AG.
Medium
Report
Prothena (NASDAQ:PRTA) was given a new $36.00 price target on by analysts at UBS Group AG.
10/28
08:09 am
prta
Prothena (NASDAQ:PRTA) had its price target raised by analysts at Piper Sandler from $15.00 to $36.00. They now have an "overweight" rating on the stock.
Low
Report
Prothena (NASDAQ:PRTA) had its price target raised by analysts at Piper Sandler from $15.00 to $36.00. They now have an "overweight" rating on the stock.
10/7
09:02 am
prta
Prothena (NASDAQ:PRTA) was given a new $20.00 price target on by analysts at HC Wainwright.
Medium
Report
Prothena (NASDAQ:PRTA) was given a new $20.00 price target on by analysts at HC Wainwright.
10/1
05:01 pm
prta
Prothena's Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer's Disease [Yahoo! Finance]
Low
Report
Prothena's Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer's Disease [Yahoo! Finance]
10/1
04:45 pm
prta
Prothena’s Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer’s Disease
Low
Report
Prothena’s Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer’s Disease